The letter, received from the the Pharmaceuticals and Medical Devices Agency of Japan, concluded that “from the result of GMP compliance review against the stipulation of Article 14-6 of the Pharmaceutical Affairs Act by PMDA, there is no issue of concern”.

Formal approval by the agency provides important further confirmation of our long term quality and safety work, and is valuable to our Japanese customers.